To the Editor: The phase 3 NIAGARA trial reported by Powles et al. (Nov. 14 issue), 1 which evaluated perioperative durvalumab with neoadjuvant chemotherapy in muscle-invasive bladder cancer ...

Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease return and more likely to survive for longer than patients who were given ...

Comparative restricted mean survival time (RMST) analysis of survival in advanced hepatocellular carcinoma (aHCC) from pivotal phase III trials: IMbrave-150, ORIENT-32, CARES-310, HIMALAYA, and CM-9DW ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Immunotherapy drug durvalumab, sold under the brand name Imfinzi, could help reduce the risk of bladder cancer progressing or returning to patients, according to a new study. Published in the New ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a 'game-changer' study. Patients with advanced ...

In February 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...